Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/107318
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pires, N. | - |
dc.contributor.author | Pinto, P. G. N. | - |
dc.contributor.author | Marçal, N | - |
dc.contributor.author | Ferreira, A. J. | - |
dc.contributor.author | Rodrigues, C. M. P. | - |
dc.contributor.author | Bárbara, C | - |
dc.date.accessioned | 2023-07-03T10:20:53Z | - |
dc.date.available | 2023-07-03T10:20:53Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 25310437 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/107318 | - |
dc.description.abstract | Chronic Obstructive Pulmonary Disease (COPD) is currently the 4th leading cause of death worldwide but is projected to be the 3rd leading cause of death by 2020. In Portugal, the estimated prevalence of COPD in the Lisbon region is 14.2%, and a large proportion of underdiagnosed disease has been detected. In 2016, a Portuguese panel of experts proposed pharmacological treatment approaches to COPD based on the evidence available at the time. However, given that the GOLD 2017 report introduced considerable changes to the 2016 version, and that new evidence has emerged regarding treatment options, these proposals need to be updated. Also, and based on several studies, the concept of Pre-GOLD patients, which has diagnostic, prognostic and therapeutic implications, is introduced, along with a proposed algorithm for the identification and treatment of these patients. | pt |
dc.language.iso | eng | pt |
dc.publisher | Elsevier | pt |
dc.relation | Novartis Portugal | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt |
dc.subject | FLAME | pt |
dc.subject | Pre-GOLD patients | pt |
dc.subject | Diagnosis | pt |
dc.subject | Algorithm | pt |
dc.subject.mesh | Administration, Inhalation | pt |
dc.subject.mesh | Algorithms | pt |
dc.subject.mesh | Bronchodilator Agents | pt |
dc.subject.mesh | Disease Progression | pt |
dc.subject.mesh | Drug Combinations | pt |
dc.subject.mesh | Fluticasone-Salmeterol Drug Combination | pt |
dc.subject.mesh | Forced Expiratory Volume | pt |
dc.subject.mesh | Glycopyrrolate | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | Indans | pt |
dc.subject.mesh | Portugal | pt |
dc.subject.mesh | Prevalence | pt |
dc.subject.mesh | Prognosis | pt |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive | pt |
dc.subject.mesh | Quinolones | pt |
dc.subject.mesh | Risk Factors | pt |
dc.subject.mesh | Severity of Illness Index | pt |
dc.title | Pharmacological treatment of COPD - New evidence | pt |
dc.type | article | - |
degois.publication.firstPage | 90 | pt |
degois.publication.lastPage | 96 | pt |
degois.publication.issue | 2 | pt |
degois.publication.title | Pulmonology | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1016/j.pulmoe.2018.10.005 | pt |
degois.publication.volume | 25 | pt |
dc.date.embargo | 2019-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | Com Texto completo | - |
crisitem.author.orcid | 0000-0002-1016-977X | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Pharmacological treatment of COPD – New evidence.pdf | 677.11 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
10
checked on May 6, 2024
WEB OF SCIENCETM
Citations
9
checked on May 2, 2024
Page view(s)
35
checked on May 7, 2024
Download(s)
15
checked on May 7, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License